First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report
First-line anti-BCMA CAR-T cell therapy is effective and safe for high-risk MM patients, even in fragile patients with multiple comorbidities.
Authors
- Yanyan Cai (ORCID: https://orcid.org/0000-0002-2779-6163)
- Jian Hou (ORCID: https://orcid.org/0000-0002-2813-5850)
- Lijing Shen (ORCID: https://orcid.org/0000-0003-2689-1991)
- Yi Zhou (ORCID: https://orcid.org/0000-0001-5195-5294)
- Weiwei Lin
- Minyue Zhang (ORCID: https://orcid.org/0000-0002-3393-215X)
- Yi Fang
- Beiwen Ni
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1564774
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00